{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:50:03Z","timestamp":1791895803122,"version":"4.3.4"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.schres.2026.09.022","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:10:02Z","timestamp":1790093402000},"page":"578-589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Defining and operationalizing negative symptom constructs in schizophrenia: A practical guide for clinicians, researchers, and industry stakeholders"],"prefix":"10.1016","volume":"297","author":[{"given":"Giulia Maria","family":"Giordano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Melillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Galderisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armida","family":"Mucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.schres.2026.09.022_bb0005","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/schbul\/sby050","article-title":"Cross-cultural validation of the 5-factor structure of negative symptoms in schizophrenia","volume":"45","author":"Ahmed","year":"2019","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2026.09.022_bb0010","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1192\/S0007125000291496","article-title":"The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations","volume":"Suppl(7)","author":"Andreasen","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2026.09.022_bb0015","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.schres.2019.04.005","article-title":"Validation of the Brief Negative Symptom Scale and its association with functioning","volume":"208","author":"Ang","year":"2019","journal-title":"Schizophr. Res."},{"issue":"1\u20132","key":"10.1016\/j.schres.2026.09.022_bb0020","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.schres.2015.07.021","article-title":"Long-term trajectories of positive and negative symptoms in first episode psychosis: a 10year follow-up study in the OPUS cohort","volume":"168","author":"Austin","year":"2015","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2026.09.022_bb0025","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/schbul\/sbx065","article-title":"Preclinical models to investigate mechanisms of negative symptoms in schizophrenia","volume":"43","author":"Barnes","year":"2017","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2026.09.022_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.112857","article-title":"Sleep disturbance and sleep-related impairment in psychotic disorders are related to both positive and negative symptoms","volume":"286","author":"Blanchard","year":"2020","journal-title":"Psychiatry Res."},{"issue":"3","key":"10.1016\/j.schres.2026.09.022_bb0035","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/YCO.0000000000000322","article-title":"Categorizing and assessing negative symptoms","volume":"30","author":"Bucci","year":"2017","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.schres.2026.09.022_bb0040","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.euroneuro.2020.03.010","article-title":"Persistent negative symptoms in recent-onset psychosis: relationship to treatment response and psychosocial functioning","volume":"34","author":"Bucci","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2026.09.022_bb0045","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/schbul\/sbl057","article-title":"Persistent negative symptoms in schizophrenia: an overview","volume":"33","author":"Buchanan","year":"2007","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2026.09.022_bb0050","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/schbul\/sbu151","article-title":"Rasagiline in the treatment of the persistent negative symptoms of schizophrenia","volume":"41","author":"Buchanan","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"7","key":"10.1016\/j.schres.2026.09.022_bb0055","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.euroneuro.2014.03.007","article-title":"A phase II\/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study","volume":"24","author":"Bugarski-Kirola","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2026.09.022_bb0060","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bjc.12248","article-title":"Understanding individuals\u2019 subjective experiences of negative symptoms of schizophrenia: a qualitative study","volume":"59","author":"Butcher","year":"2020","journal-title":"Br. J. Clin. Psychol."},{"issue":"5","key":"10.1016\/j.schres.2026.09.022_bb0065","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1176\/ajp.145.5.578","article-title":"Deficit and nondeficit forms of schizophrenia: the concept","volume":"145","author":"Carpenter","year":"1988","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2026.09.022_bb0070","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2025.12.019","article-title":"Association between negative symptoms and health-related quality of life and functional outcomes in persons with schizophrenia: a systematic review","volume":"288","author":"Chan","year":"2026","journal-title":"Schizophr. Res."},{"issue":"17","key":"10.1016\/j.schres.2026.09.022_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17176227","article-title":"Neuroanatomy of patients with deficit schizophrenia: an exploratory quantitative meta-analysis of structural neuroimaging studies","volume":"17","author":"Chee","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"1","key":"10.1016\/j.schres.2026.09.022_bb0080","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1192\/bjp.2023.51","article-title":"The emergence of primary negative symptoms: relevance of timing?","volume":"223","author":"Chen","year":"2023","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2026.09.022_bb0085","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/NDT.S225643","article-title":"Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment","volume":"16","author":"Correll","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.schres.2026.09.022_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2025.116406","article-title":"A systematic review and synthesis of 489 studies investigating treatments for negative symptoms in the schizophrenia spectrum: trial designs, demographics and clinical characteristics","volume":"347","author":"Damiani","year":"2025","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2026.09.022_bb0095","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-026-03543-1","article-title":"Interventions for negative symptoms in schizophrenia: efficacy and clinical interpretability in a meta-analysis of 451 randomized controlled trials","author":"Damiani","year":"2026","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.09.022_bb0100","doi-asserted-by":"crossref","DOI":"10.1038\/s41537-023-00372-x","article-title":"Interplay between negative symptoms, time spent doing nothing, and negative emotions in patients with schizophrenia spectrum disorders: results from a 37-site study","volume":"9","author":"D\u2019Anna","year":"2023","journal-title":"Schizophrenia"},{"issue":"3","key":"10.1016\/j.schres.2026.09.022_bb0105","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/schbul\/sbac013","article-title":"Efficacy and safety of roluperidone for the treatment of negative symptoms of schizophrenia","volume":"48","author":"Davidson","year":"2022","journal-title":"Schizophr. Bull."},{"issue":"10","key":"10.1016\/j.schres.2026.09.022_bb0110","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1176\/appi.ajp.2020.20070968","article-title":"Sleep abnormalities in schizophrenia: state of the art and next steps","volume":"178","author":"Ferrarelli","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2026.09.022_bb0115","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eurpsy.2014.01.007","article-title":"Impact of primary negative symptoms on functional outcomes in schizophrenia","volume":"29","author":"Fervaha","year":"2014","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.schres.2026.09.022_bb0120","series-title":"FDA Public Meeting","article-title":"Evaluating the negative symptoms of schizophrenia in clinical trials","author":"Fischer","year":"2024"},{"issue":"4","key":"10.1016\/j.schres.2026.09.022_bb0125","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/schbul\/sbu170","article-title":"Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials","volume":"41","author":"Fusar-Poli","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2026.09.022_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2022.115043","article-title":"Negative symptoms of schizophrenia: trying to answer unanswered research questions","volume":"320","author":"Galderisi","year":"2023","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2026.09.022_bb0135","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.euroneuro.2023.06.008","article-title":"A new approach to negative symptoms of schizophrenia","volume":"75","author":"Galderisi","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2026.09.022_bb0140","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.euroneuro.2012.04.019","article-title":"Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial","volume":"23","author":"Galderisi","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2026.09.022_bb0145","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/wps.20167","article-title":"The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia","volume":"13","author":"Galderisi","year":"2014","journal-title":"World Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2026.09.022_bb0150","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.schres.2016.04.043","article-title":"Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives","volume":"175","author":"Galderisi","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2026.09.022_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2016.04.046","article-title":"Dissecting negative symptoms of schizophrenia: history, assessment, pathophysiological mechanisms and treatment","volume":"186","author":"Galderisi","year":"2017","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.schres.2026.09.022_bb0160","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S2215-0366(18)30050-6","article-title":"Negative symptoms of schizophrenia: new developments and unanswered research questions","volume":"5","author":"Galderisi","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.09.022_bb0165","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/wps.20700","article-title":"The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients","volume":"19","author":"Galderisi","year":"2020","journal-title":"World Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.09.022_bb0170","article-title":"EPA guidance on assessment of negative symptoms in schizophrenia","volume":"64","author":"Galderisi","year":"2021","journal-title":"Eur. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.09.022_bb0175","article-title":"EPA guidance on treatment of negative symptoms in schizophrenia","volume":"64","author":"Galderisi","year":"2021","journal-title":"Eur. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2026.09.022_bb0180","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/wps.21230","article-title":"Ethical challenges in contemporary psychiatry: an overview and an appraisal of possible strategies and research needs","volume":"23","author":"Galderisi","year":"2024","journal-title":"World Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.09.022_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11010061","article-title":"Investigating the relationship between white matter connectivity and motivational circuits in subjects with deficit schizophrenia: a diffusion tensor imaging (DTI) study","volume":"11","author":"Giordano","year":"2021","journal-title":"J. Clin. Med."},{"issue":"7","key":"10.1016\/j.schres.2026.09.022_bb0190","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1080\/14737175.2022.2092402","article-title":"Updated perspectives on the clinical significance of negative symptoms in patients with schizophrenia","volume":"22","author":"Giordano","year":"2022","journal-title":"Expert. Rev. Neurother."},{"issue":"1","key":"10.1016\/j.schres.2026.09.022_bb0195","doi-asserted-by":"crossref","DOI":"10.1192\/j.eurpsy.2023.2478","article-title":"External validation of the five domains of negative symptoms: focus on cognition, functional capacity, and real-world functioning","volume":"67","author":"Giordano","year":"2024","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.schres.2026.09.022_bb0200","article-title":"Negative symptoms and social cognition as mediators of the relationship between neurocognition and functional outcome in schizophrenia","volume":"15","author":"Giordano","year":"2024","journal-title":"Front. Psychol."},{"issue":"1","key":"10.1016\/j.schres.2026.09.022_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41537-024-00545-2","article-title":"Investigating the causal pathways among psychopathological variables, cognitive impairment, and real-life functioning in people with schizophrenia","volume":"11","author":"Giuliani","year":"2025","journal-title":"Schizophrenia"},{"issue":"1","key":"10.1016\/j.schres.2026.09.022_bb0210","doi-asserted-by":"crossref","DOI":"10.1038\/s41537-026-00739-w","article-title":"Persistent negative symptoms in the EULAST cohort: impact on functional outcome","volume":"12","author":"Giuliani","year":"2026","journal-title":"Schizophrenia"},{"issue":"5","key":"10.1016\/j.schres.2026.09.022_bb0215","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00213-021-05801-2","article-title":"Cannabinoids, reward processing, and psychosis","volume":"239","author":"Gunasekera","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2026.09.022_bb0220","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.schres.2024.07.011","article-title":"Prevalence of prominent and predominant negative symptoms across different criteria for negative symptom severity and minimal positive symptoms: a comparison of different criteria","volume":"271","author":"Harvey","year":"2024","journal-title":"Schizophr. Res."},{"issue":"2\u20133","key":"10.1016\/j.schres.2026.09.022_bb0225","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.schres.2011.06.030","article-title":"Development and psychometric validation of the Clinical Assessment Interview for Negative Symptoms (CAINS)","volume":"132","author":"Horan","year":"2011","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2026.09.022_bb0230","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2026.09.022_bb0235","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0165-1781(89)90153-4","article-title":"The schedule for the deficit syndrome: an instrument for research in schizophrenia","volume":"30","author":"Kirkpatrick","year":"1989","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.schres.2026.09.022_bb0240","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2026.09.022_bb0245","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/schbul\/sbq059","article-title":"The brief negative symptom scale: psychometric properties","volume":"37","author":"Kirkpatrick","year":"2011","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.schres.2026.09.022_bb0250","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/schbul\/sbab069","article-title":"Primary negative symptoms: refining the research target","volume":"47","author":"Kirkpatrick","year":"2021","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2026.09.022_bb0255","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2016.05.003","article-title":"Secondary negative symptoms \u2014 a review of mechanisms, assessment and treatment","volume":"186","author":"Kirschner","year":"2017","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.schres.2026.09.022_bb0260","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/acps.12873","article-title":"The relationship between negative symptoms and depression in schizophrenia: a systematic review","volume":"137","author":"Krynicki","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.schres.2026.09.022_bb0265","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jalz.2016.05.008","article-title":"Apathy associated with neurocognitive disorders: recent progress and future directions","volume":"13","author":"Lanct\u00f4t","year":"2017","journal-title":"Alzheimers Dement."},{"issue":"2","key":"10.1016\/j.schres.2026.09.022_bb0270","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/schbul\/sbi039","article-title":"Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim","volume":"32","author":"Laughren","year":"2006","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2026.09.022_bb0275","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/wps.20385","article-title":"The current conceptualization of negative symptoms in schizophrenia","volume":"16","author":"Marder","year":"2017","journal-title":"World Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2026.09.022_bb0280","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.euroneuro.2013.10.016","article-title":"Defining and measuring negative symptoms of schizophrenia in clinical trials","volume":"24","author":"Marder","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2026.09.022_bb0285","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.schres.2023.07.010","article-title":"Negative symptoms in schizophrenia: newly emerging measurements, pathways, and treatments","volume":"258","author":"Marder","year":"2023","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2026.09.022_bb0290","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/schbul\/sbq161","article-title":"Methodological issues in negative symptom trials","volume":"37","author":"Marder","year":"2011","journal-title":"Schizophr. Bull."},{"issue":"2\u20133","key":"10.1016\/j.schres.2026.09.022_bb0295","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.schres.2013.07.058","article-title":"Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia","volume":"150","author":"Marder","year":"2013","journal-title":"Schizophr. Res."},{"issue":"2\u20133","key":"10.1016\/j.schres.2026.09.022_bb0300","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.schres.2013.10.005","article-title":"Clinical trials for negative symptoms\u2014emerging directions and unresolved issues","volume":"150","author":"Marder","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2026.09.022_bb0305","series-title":"Minerva Neurosciences Receives Complete Response Letter From FDA for New Drug Application for Roluperidone","author":"Minerva Neurosciences, I","year":"2024"},{"key":"10.1016\/j.schres.2026.09.022_bb0310","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2016.05.014","article-title":"Primary and persistent negative symptoms: concepts, assessments and neurobiological bases","volume":"186","author":"Mucci","year":"2017","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.schres.2026.09.022_bb0315","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.euroneuro.2019.05.006","article-title":"A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale","volume":"29","author":"Mucci","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2026.09.022_bb0320","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1001\/jamapsychiatry.2020.4614","article-title":"Factors associated with real-life functioning in persons with schizophrenia in a 4-year follow-up study of the Italian network for research on psychoses","volume":"78","author":"Mucci","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"10074","key":"10.1016\/j.schres.2026.09.022_bb0325","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","article-title":"Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial","volume":"389","author":"N\u00e9meth","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.schres.2026.09.022_bb0330","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/pcn.12848","article-title":"Social anxiety and negative symptoms as the characteristics of patients with schizophrenia who show competence-performance discrepancy in social functioning","volume":"73","author":"Nemoto","year":"2019","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2026.09.022_bb0335","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1192\/bjp.183.1.50","article-title":"Institutionalisation and schizophrenia in Japan: social environments and negative symptoms: nationwide survey of in-patients","volume":"183","author":"Oshima","year":"2003","journal-title":"Br. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2026.09.022_bb0340","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1080\/08039488.2021.2015431","article-title":"Longitudinal persistence of negative symptoms in young individuals with first episode schizophrenia: a 24-month multi-modal program follow-up","volume":"76","author":"Pelizza","year":"2022","journal-title":"Nord. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.09.022_bb0345","first-page":"28","article-title":"Memory and learning impairments in deficit and non-deficit schizophrenia: a scoping review","volume":"35","author":"Plichta","year":"2026","journal-title":"Postep. Psychiatr. Neurol."},{"issue":"6","key":"10.1016\/j.schres.2026.09.022_bb0350","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00406-024-01808-w","article-title":"Persistent negative symptoms in young people at clinical high risk of psychosis treated with an Italian early intervention program: a longitudinal study","volume":"274","author":"Ricci","year":"2024","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"15","key":"10.1016\/j.schres.2026.09.022_bb0355","article-title":"Anhedonia and negative symptoms in first-episode psychosis: a systematic review and meta-analysis of prevalence, mechanisms, and clinical implications","volume":"13","author":"Ricci","year":"2025","journal-title":"Healthcare (Basel)"},{"issue":"5","key":"10.1016\/j.schres.2026.09.022_bb0360","doi-asserted-by":"crossref","DOI":"10.1192\/bjo.2023.541","article-title":"The structure stability of negative symptoms: longitudinal network analysis of the Brief Negative Symptom Scale in people with schizophrenia","volume":"9","author":"Rucci","year":"2023","journal-title":"BJPsych Open"},{"key":"10.1016\/j.schres.2026.09.022_bb0365","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.neubiorev.2020.07.007","article-title":"Cannabis, nicotine and the negative symptoms of schizophrenia: systematic review and meta-analysis of observational studies","volume":"116","author":"Sabe","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.schres.2026.09.022_bb0370","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cpr.2017.09.007","article-title":"Predictors of functional recovery in first-episode psychosis: a systematic review and meta-analysis of longitudinal studies","volume":"58","author":"Santesteban-Echarri","year":"2017","journal-title":"Clin. Psychol. Rev."},{"issue":"1","key":"10.1016\/j.schres.2026.09.022_bb0375","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.schres.2014.12.001","article-title":"Defining therapeutic benefit for people with schizophrenia: focus on negative symptoms","volume":"162","author":"Schooler","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2026.09.022_bb0380","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12888-014-0225-8","article-title":"Impact of negative symptoms on healthcare resource utilization and associated costs in adult outpatients with schizophrenia: a population-based study","volume":"14","author":"Sicras-Mainar","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2026.09.022_bb0385","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jamapsychiatry.2018.2475","article-title":"The latent structure of negative symptoms in schizophrenia","volume":"75","author":"Strauss","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2026.09.022_bb0390","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/schbul\/sby133","article-title":"Network analysis reveals the latent structure of negative symptoms in schizophrenia","volume":"45","author":"Strauss","year":"2019","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2026.09.022_bb0395","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.schres.2026.05.008","article-title":"Subjective perceptions of negative symptoms among outpatients with schizophrenia and their relatives or caregivers: definitions, importance, measurement, and desired improvement","volume":"295","author":"Strauss","year":"2026","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.schres.2026.09.022_bb0400","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","article-title":"Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study","volume":"71","author":"Umbricht","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2026.09.022_bb0405","doi-asserted-by":"crossref","DOI":"10.1093\/schbul\/sbaf073","article-title":"Economic burden associated with negative symptoms identified through natural language processing among patients with schizophrenia in the United States","volume":"52","author":"Vaccaro","year":"2026","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2026.09.022_bb0410","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.schres.2018.07.013","article-title":"A meta-analysis of factors associated with quality of life in first episode psychosis","volume":"202","author":"Watson","year":"2018","journal-title":"Schizophr. Res."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426003166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426003166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:09:08Z","timestamp":1791893348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996426003166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":82,"alternative-id":["S0920996426003166"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2026.09.022","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Defining and operationalizing negative symptom constructs in schizophrenia: A practical guide for clinicians, researchers, and industry stakeholders","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2026.09.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}